LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII) today announced that 32 scientific abstracts will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8 in Chicago, evaluating the use of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension). The clinical findings of this nab-driven chemotherapy will be presented in the treatment of multiple tumor types, including some of the most difficult-to-treat cancers.
